| Basics |
Axsome Therapeutics, Inc.
Axsome Therapeutics Inc is a pharmaceutical company in the United States. It focuses on developing novel therapeutics for the redressal of diseases related to the central nervous system.
|
| IPO Date: |
November 19, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$7.52B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.18 | 2.93%
|
| Avg Daily Range (30 D): |
$2.64 | 1.91%
|
| Avg Daily Range (90 D): |
$2.08 | 1.65%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
.46M |
| Avg Daily Volume (90 D): |
.45M |
| Trade Size |
| Avg Trade Size (Sh.): |
75 |
| Avg Trade Size (Sh.) (30 D): |
38 |
| Avg Trade Size (Sh.) (90 D): |
37 |
| Institutional Trades |
| Total Inst.Trades: |
3,472 |
| Avg Inst. Trade: |
$3.08M |
| Avg Inst. Trade (30 D): |
$5.57M |
| Avg Inst. Trade (90 D): |
$5.82M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.83M |
| Avg Closing Trade (30 D): |
$7.97M |
| Avg Closing Trade (90 D): |
$7.12M |
| Avg Closing Volume: |
53.59K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-4.67
|
$-.94
|
$-.97
|
|
Diluted EPS
|
$-4.67
|
$-.94
|
$-.97
|
|
Revenue
|
$ 561.26M
|
$ 170.99M
|
$ 150.04M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -229.53M
|
$ -47.23M
|
$ -47.97M
|
|
Operating Income / Loss
|
$ -212.42M
|
$ -46.11M
|
$ -36.71M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -2.07M
|
$ 22.26M
|
$ 2.11M
|
|
PE Ratio
|
|
|
|
|
|
|
